Shire Receives Outperform Rating from BNP Paribas (SHP)
Shire (LON:SHP)‘s stock had its “outperform” rating reaffirmed by equities researchers at BNP Paribas in a research report issued on Tuesday, Analyst RN reports. They currently have a GBX 3,100 ($50.84) target price on the stock. BNP Paribas’ target price would indicate a potential upside of 8.01% from the company’s current price.
Shares of Shire (LON:SHP) traded up 0.74% during mid-day trading on Tuesday, hitting GBX 2870.00. The stock had a trading volume of 845,810 shares. Shire has a one year low of GBX 1853.00 and a one year high of GBX 2939.00. The stock has a 50-day moving average of GBX 2785.91 and a 200-day moving average of GBX 2529.58. The company’s market cap is £15.739 billion.
SHP has been the subject of a number of other recent research reports. Analysts at AlphaValue upgraded shares of Shire to a “reduce” rating in a research note to investors on Tuesday. They now have a GBX 2,884.10 ($47.30) price target on the stock, up previously from GBX 2,883.10 ($47.29). Separately, analysts at FinnCap reiterated a “buy” rating on shares of Shire in a research note to investors on Tuesday. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Shire in a research note to investors on Monday. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Shire presently has a consensus rating of “Buy” and a consensus price target of GBX 2,497.52 ($40.96).
Shire plc (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.